[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunosuppressive-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunosuppressive-treatment":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100593730",false,"NCT07010237","Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia","Dose-attenuated IST and Hetrombopag in the Treatment of Elderly (≥65 Years) Patients With Very Severe\u002FSevere Aplastic Anemia: A Single-Center, Single-Arm, Phase IIB Clinical Study on Efficacy and Safety","Inclusion Criteria:\n\n* Clinical diagnosis of VSAA\u002FSAA.\n* Age ≥65 years.\n* Completion of all screening assessments.\n* Must be able to swallow tablets.\n* Signed informed consent (by patient or legal guardian if patient is incapacitated).\n\nExclusion Criteria:\n\n* Clonal cytogenetic abnormalities (excluding isolated -Y or +8).\n* Prior treatment with ATG\u002Fhigh-dose cyclophosphamide.\n* Prior cyclosporine\u002Ftacrolimus use \\>12 months.\n* Prior TPO-RA therapy \\>3 months.\n* Uncontrolled malignancies or conditions contraindicating ATG.\n* Severe organ dysfunction (e.g., creatinine ≥177 μmol\u002FL).\n* Investigator judgment of unsuitability.","ALL","65 Years",{"count":18,"type":19},65,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA\u002FSAA.",[25,26,27],"Sever Aplastic Anaemia","Elderly (People Aged 65 or More)","Immunosuppressive Treatment","RECRUITING","2025-06-05",{"date":31,"type":32},"2025-06-08","ACTUAL",{"date":34,"type":32},"2025-02-01",{"date":36,"type":19},"2029-07-01",{"name":38,"class":39},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",""]